Abstract: The invention provides an auranofin-releasing antibacterial and antibiofilm polyurethane (PU) catheter coating. Auranofin is an antirheumatic drug with recently identified antimicrobial properties.

Abstract: Described herein are techniques to aid clinicians and researchers in determining a condition of connective tissue as it relates to tissue development, growth and maturation, tissue remodeling and healing following injury, and risk of injury based on a magnetic resonance (MR) image of the tissue. Such techniques may be useful to clinicians by providing insights on factors that influence the growth and maturation of connective tissues as well as those that impact the risk of connective tissue injury and response to treatment. These insights can be used in a variety of ways, including to guide or develop patient specific risk assessment and prevention strategies, treatment plans, and postoperative care plans for individuals at risk of connective tissue injuries and those with injured connective tissues, such as an anterior cruciate ligament (ACL) injury.

Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Abstract: The present application provides that synthetic retinoid compounds are useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. faecalis, E. faecium, B. subtilis, and B. anthracis. The present application also provides a tricyclic fluoroquinolone compound, Z3060, useful in methods of treating bacterial infections, such as a bacterial infection caused by S. aureus, methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), E. spp., K. pneumoniae, P. aeruginosa, A. baumannii, E. faecium, and E. faecalis. Also provided herein is a gold compound, auranofin, useful in treating bacterial and fungal infections, such as a fungal infection caused by C. albicans, C. parapsilosis, C. tropicalis, C. glabrata, and C. neoformans.

Abstract: The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.

Abstract: Provided herein are methods, compositions and kits for preventing and treating malaria. Also included herein are kits for preventing and treating malaria.

Abstract: The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.

Abstract: A system includes intracranial electrodes embedded into a cranium, a deep brain stimulation system embedded into the cranium, a brain implantable device embedded into the cranium, and a pulse generator, the deep brain stimulation system and the brain implantable device linked to the intracranial electrodes and to the pulse generator.

Abstract: This invention is directed to, inter alia, stable cartilage-derived progenitor cell lines as well as methods for producing stable cartilage-derived progenitor cell lines from diseased human cartilaginous tissues and lesions. Also provided herein are methods for using cartilage-derived progenitor cell lines for treatment of cartilage and bone degenerative diseases.

Abstract: Compositions or an assembly of a series of biomimetic compounds include chemical structures that mimic or structurally resemble a nucleic acid base pair. Complexes of nanotubes and agents are useful to deliver agents into the cells or bodily tissues of individuals for therapeutic and diagnostic purposes. Exemplary compounds include those of Formula (I), (III), (V) or (VII), or of Formula (II), (IV), (VI) or (VIII).

Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.

Abstract: Ferritin or iron-based image enhancement agents identify target tissue for treatment or ablation and are heated by microwave absorption. Microwave heat substrates enhance microwave hyperthermal ablation treatment, and may be percutaneously delivered and imaged by x-ray CT during placement of the microwave treatment antenna, allowing more precise positioning and more complete ablation of a tumor site. One method of treating a target tissue uses image-guided delivery of a heat substrate with a reverse-phase change polymer, and may apply energy to fix a mass of the material in the tissue. The fixed polymer may increase hyperthermia, form a thermal boundary, or blockade a vessel or passage so as to reduce or prevent undesired conductive cooling by contiguous tissue, or may deliver a localized treatment drug at the site, upon heating or as it degrades over time.

Abstract: The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.

Abstract: The invention provides a method and bacterial compositions for reducing or preventing an infection of a bodily tissue by a fungal microorganism by contacting the tissue with a composition comprising a purified Lactobacillus paracasei bacterium.

Abstract: The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.

Abstract: Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated with H. pylori in a subject infected by H. pylori, the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.

Abstract: This invention is directed to, inter alia, compositions and methods for restoring normal microRNA (miR) expression in chondrosarcoma cells as well as methods for treating and diagnosing chondrosarcoma in individuals in need thereof.

Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.

Abstract: The current subject matter provides a tool for evaluating the risk of failure or the likelihood of success of surgery of healing ligaments and tendons in the body. In some embodiments, a region of a scan comprising one or more of an anterior cruciate ligament (ACL) or an ACL graft can be defined. A magnetic resonance (MR) imaging data set can be obtained. MR parameters characterizing a size and a quality of the ACL or ACL graft can be derived using the MR data. The MR parameters can be used as inputs to a predictive model. A score characterizing a likelihood of failure of the ACL or ACL graft in a human patient can be generated using the predictive model.

Abstract: The present disclosure relates to antibodies that bind human chitinase-3-like protein 1 (CHI3L1) and uses thereof. In aspects, the antibodies are useful in compositions and methods for detecting and/or treating nonalcoholic steatohepatitis (NAFLD) or nonalcoholic fatty liver disease (NASH) in a subject, as well as subsequent complications of untreated progression in the liver of a subject, such as liver cirrhosis and/or a hepatocellular carcinoma.